AGP Executive Report
Last update: 4 hours agoChikungunya Vaccine: UK regulators have withdrawn authorization for Valneva’s IXCHIQ after reviewing existing safety data. The company says no new safety issue prompted the decision and will not appeal. The withdrawal applies only to the UK; authorizations in the EU, Canada, Brazil and other markets remain unchanged. The US license was suspended in 2025.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.